Researchers around the world use publicly available Ivy Glioblastoma Atlas Project to investigate aggressive brain cancer
PHOENIX, Ariz., and SEATTLE, Wash. — May 11, 2018 — This year, an estimated 13,000 Americans will be diagnosed with glioblastoma, which is the most deadly and aggressive form of brain cancer.
In the ongoing pursuit of new therapies, a growing number of researchers studying the disease are using the Ivy Glioblastoma Atlas Project (Ivy GAP): a publicly available anatomic transcriptional atlas of human glioblastoma. A report on the Ivy GAP and the associated Ivy GAP Clinical and Genomic Database published May 10 in the journal Science.
“This visionary contribution provides researchers with a map of glioblastoma that can direct researchers right up to the doorstep of this disease and opens the door to its biology at a scale never before thought possible,” said Dr. Michael Berens, a Deputy Director of the Translational Genomics Research Institute (TGen), head of TGen’s Glioma Research Lab, and one of the study’s co-authors.
“It sets the stage for researchers to conduct more detailed analysis, characterize micro-environments, and understand how tumor cells interact with host cells. These studies will lead to improved clinical outcomes by pointing to novel therapeutic targets in future patients,” said Dr. Berens, who helped select the genes explored in the study and linked up labs to provide tissue samples
Led by researchers at the Allen Institute for Brain Science and Swedish Neuroscience Institute, and funded with grants from The Ben and Catherine Ivy Foundation, Ivy GAP includes detailed information about genes expressed in the many anatomical regions of glioblastoma.
“Our mission at the Allen Institute for Brain Science is to accelerate the understanding of how the human brain works in health and disease,” said Dr. Mike Hawrylycz. “The Ivy GAP gives researchers around the world a foundational resource for exploring the anatomic and genetic basis of glioblastoma at the cellular and molecular levels.”
“The Ivy Glioblastoma Project allows investigators to access massive amounts of tumor genomic information and patient clinical information,” says Dr. Charles Cobbs, the Gregory Foltz, M.D., endowed director of The Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment at the Swedish Neuroscience Institute. “The new knowledge resulting from universal access to the atlas is leading to advances in our understanding of the biology of glioblastoma.”
The goal of Ivy GAP is to provide online resources to scientists and physicians dedicated to the development of innovative treatments and diagnostics that will enhance the quality of life and survival of patients with brain cancer.
“Glioblastoma is one of the most aggressive of all cancers and it affects people of all ages. I am hopeful that the Ivy GAP tool will be a stepping stone for all scientists to move closer to a cure for brain cancer,” said Catherine Bracken Ivy, Founder and President of The Ben & Catherine Ivy Foundation.
“It’s gratifying to see this project used by so many investigators in the research community to address clinically-relevant questions,” said Ralph Puchalski, lead scientist on the project, now at the Swedish Neuroscience Institute. “Several recent studies which used the Ivy GAP demonstrate the impact it’s having in the field of neuro-oncology.”
“The Ivy GAP datasets are major resources for researchers in the field of neuro-oncology, particularly in the developing field of cancer stem cells,” said Dr. Maciej S. Lesniak, Neurosurgeon-in-Chief at Northwestern Memorial Hospital. Dr. Lesniak and his team used Ivy GAP’s local regional tumor analysis to more effectively identify drug target site efficacy in patients with glioblastoma. The results of this research were published in the Proceedings of the National Academy of Sciences.
Another team of researchers, led by neuro-oncologist Dr. Jeremy Rich, Clinical Professor at the University of California San Diego School of Medicine, used the Ivy GAP in their quest to better understand the molecular mechanisms in glioblastoma tumors. Results of their studies were published in the journals Nature and Nature Medicine.
“Glioblastomas show striking diversity throughout the tumor, which is ignored in most scientific studies,” said Dr. Rich, who also is Director of Neuro-Oncology and the Brain Tumor Institute at UCSD School of Medicine. “As a clinician, I routinely witness our treatments work differently in different parts of the tumor, suggesting that the differences in location are critical to the outcome of patients.
“We have been using the Ivy GAP resource to understand how novel targets are differentially expressed within the tumor, which has allowed us to identify therapeutic strategies in development for clinical trials. This is a critical resource that benefits the whole community fighting this lethal cancer,” Dr. Rich said.
# # #
About Translational Genomics Institute (TGen)
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is focused on helping patients with neurological disorders, cancer, diabetes, and infectious diseases, through cutting edge translational research (the process of rapidly moving research towards patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. TGen is affiliated with City of Hope, a world-renowned independent research and cancer and diabetes treatment center: www.cityofhope.org. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. For more information, visit: www.tgen.org. Follow TGen on Facebook, LinkedIn and Twitter @TGen
TGen Senior Science Writer
About The Ben & Catherine Ivy Foundation
The Ben & Catherine Ivy Foundation, based in Scottsdale, Ariz., was formed in 2005, when Ben Ivy lost his battle with glioblastoma multiforme (GBM). Since then, the Foundation has contributed more than $82 million to research in gliomas within the United States and Canada, with the goal of better diagnostics and treatments that offer long-term survival and a high quality of life for patients with brain tumors. The Ben & Catherine Ivy Foundation is the largest privately funded foundation of its kind in the United States. For more information, visit www.ivyfoundation.org.
About the Allen Institute for Brain Science
The Allen Institute for Brain Science is a division of the Allen Institute (alleninstitute.org), an independent, 501(c)(3) nonprofit medical research organization, and is dedicated to accelerating the understanding of how the human brain works in health and disease. Using a big science approach, the Allen Institute generates useful public resources used by researchers and organizations around the globe, drives technological and analytical advances, and discovers fundamental brain properties through integration of experiments, modeling and theory. Launched in 2003 with a seed contribution from founder and philanthropist Paul G. Allen, the Allen Institute is supported by a diversity of government, foundation and private funds to enable its projects. The Allen Institute for Brain Science’s data and tools are publicly available online at brain-map.org.
Sr. Manager, Media Relations
About Swedish Medical Center
Founded in 1910, Swedish is the largest non-profit health provider in the Greater Seattle area. It is comprised of five hospital campuses (First Hill, Cherry Hill, Ballard, Edmonds and Issaquah); ambulatory care centers in Redmond and Mill Creek; and Swedish Medical Group, a network of more than 170 primary-care and specialty clinics located throughout the Greater Puget Sound area. In addition to general medical and surgical care including robotic-assisted surgery, Swedish is known as a regional referral center, providing specialized treatment in areas such as cardiovascular care, cancer care, neuroscience, orthopedics, high-risk obstetrics, pediatric specialties, organ transplantation and clinical research. In 2017, Swedish provided nearly $200 million on community benefit programs in Western Washington, including $23.9 million in free and discounted care. For more information, visit www.swedish.org, www.facebook.com/swedishmedicalcenter, or www.twitter.com/swedish.